A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 with Recent Onset Stage 3 Type 1 Diabetes
Clinical Trial Grant
Awarded By
COUR Pharmaceuticals Development Co., Inc.
Start Date
September 16, 2025
End Date
June 26, 2034
Awarded By
COUR Pharmaceuticals Development Co., Inc.
Start Date
September 16, 2025
End Date
June 26, 2034